# 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

> **NCT00456586** · PHASE2 · COMPLETED · sponsor: **Kyowa Kirin, Inc.** · enrollment: 180 (—)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** KW-6002 (istradefylline)

## Key facts

- **NCT ID:** NCT00456586
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2003-05
- **Final completion:** 2003-06
- **Target enrollment:** 180 (—)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456586, "12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00456586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*